BR0012568A - Phosphate transport inhibitors - Google Patents

Phosphate transport inhibitors

Info

Publication number
BR0012568A
BR0012568A BR0012568-7A BR0012568A BR0012568A BR 0012568 A BR0012568 A BR 0012568A BR 0012568 A BR0012568 A BR 0012568A BR 0012568 A BR0012568 A BR 0012568A
Authority
BR
Brazil
Prior art keywords
transport inhibitors
phosphate transport
phosphate
sulfonamidobenzamides
revealed
Prior art date
Application number
BR0012568-7A
Other languages
Portuguese (pt)
Inventor
Richard M Edwards
Robert G Franz
Dimitri Gaitanopoulos
Joseph Weinstock
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of BR0012568A publication Critical patent/BR0012568A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"INIBIDORES DO TRANSPORTE DE FOSFATO". N-aril-2-sulfonamidobenzamidas, úteis no tratamento de deficiência renal crónica e doença urêmica óssea, são reveladas."PHOSPHATE TRANSPORT INHIBITORS". N-aryl-2-sulfonamidobenzamides, useful in the treatment of chronic kidney deficiency and uremic bone disease, are revealed.

BR0012568-7A 1999-07-20 2000-07-19 Phosphate transport inhibitors BR0012568A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14464699P 1999-07-20 1999-07-20
PCT/US2000/019616 WO2001005398A1 (en) 1999-07-20 2000-07-19 Phosphate transport inhibitors

Publications (1)

Publication Number Publication Date
BR0012568A true BR0012568A (en) 2002-04-30

Family

ID=22509500

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0012568-7A BR0012568A (en) 1999-07-20 2000-07-19 Phosphate transport inhibitors

Country Status (19)

Country Link
EP (1) EP1202729A1 (en)
JP (1) JP2003504403A (en)
KR (1) KR20020015382A (en)
CN (1) CN1361687A (en)
AR (1) AR030911A1 (en)
AU (1) AU6354300A (en)
BR (1) BR0012568A (en)
CA (1) CA2379657A1 (en)
CO (1) CO5190714A1 (en)
CZ (1) CZ2002204A3 (en)
HU (1) HUP0202938A3 (en)
IL (1) IL147697A0 (en)
MX (1) MXPA02000753A (en)
NO (1) NO20020278D0 (en)
NZ (1) NZ516619A (en)
PL (1) PL353741A1 (en)
TR (1) TR200200112T2 (en)
WO (1) WO2001005398A1 (en)
ZA (1) ZA200200464B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL152587A0 (en) * 2000-05-12 2003-05-29 Smithkline Beecham Corp Phosphate transport inhibitors
GB2378179A (en) * 2001-08-03 2003-02-05 Pantherix Ltd Aromatic sulfonamides and their use in treating bacterial diseases
AUPR738301A0 (en) * 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
US7119120B2 (en) * 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
AU2005299771A1 (en) 2004-10-21 2006-05-04 High Point Pharmaceuticals, Llc Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use
EP1839655A1 (en) * 2005-01-20 2007-10-03 Shionogi Co., Ltd. Ctgf expression inhibitor
WO2009146875A1 (en) * 2008-06-03 2009-12-10 Fresenius Medical Care Deutschland Gmbh Pharmaceutical compositions comprising gamma secretase modulators
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CN103819403B (en) 2008-12-31 2017-01-04 阿德利克斯公司 For treating the disease relevant with fluid retention or salt over loading and the Compounds and methods for of disorder of gastrointestinal tract
US8664425B2 (en) * 2010-02-02 2014-03-04 Honeywell International Inc. Bluegreen fluorescent compounds
ES2547890T3 (en) 2010-07-07 2015-10-09 Ardelyx, Inc. Compounds and methods to inhibit phosphate transport
JP5827327B2 (en) 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド Compounds and methods for inhibiting phosphate transport
WO2012054110A2 (en) * 2010-07-07 2012-04-26 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
JP5827328B2 (en) * 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド Compounds and methods for inhibiting phosphate transport
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
AU2013304812B2 (en) 2012-08-21 2016-06-09 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CN103183623A (en) * 2013-03-12 2013-07-03 中国医学科学院医药生物技术研究所 A group of benzene sulfonamido benzamide derivatives, and preparation and application thereof
KR20230132619A (en) 2013-04-12 2023-09-15 알데릭스, 인코포레이티드 Nhe3-binding compounds and methods for inhibiting phosphate transport
CN105395532B (en) * 2015-11-25 2017-11-14 中国医学科学院医药生物技术研究所 Application of the 2 benzene sulfonamido benzamide compounds in liver injury protection and liver fibrosis preventing and treating
EP3508475A4 (en) * 2016-08-30 2020-04-15 Nippon Soda Co., Ltd. Sulfonylamino benzamide compound and pest control agent
AU2018205400B2 (en) 2017-01-09 2022-07-14 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
EP3565811A1 (en) 2017-01-09 2019-11-13 Ardelyx, Inc. Inhibitors of nhe-mediated antiport

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86462A (en) * 1987-05-29 1992-12-01 Fujisawa Pharmaceutical Co Alkanesulfonanilide derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same
US5210079A (en) * 1988-01-07 1993-05-11 E. I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists

Also Published As

Publication number Publication date
NZ516619A (en) 2004-02-27
HUP0202938A3 (en) 2006-07-28
WO2001005398A1 (en) 2001-01-25
PL353741A1 (en) 2003-12-01
IL147697A0 (en) 2002-08-14
CZ2002204A3 (en) 2002-11-13
ZA200200464B (en) 2003-04-30
KR20020015382A (en) 2002-02-27
TR200200112T2 (en) 2002-05-21
JP2003504403A (en) 2003-02-04
CA2379657A1 (en) 2001-01-25
CN1361687A (en) 2002-07-31
HUP0202938A2 (en) 2003-01-28
AU6354300A (en) 2001-02-05
EP1202729A1 (en) 2002-05-08
MXPA02000753A (en) 2002-07-22
AR030911A1 (en) 2003-09-03
CO5190714A1 (en) 2002-08-29
NO20020278L (en) 2002-01-18
NO20020278D0 (en) 2002-01-18

Similar Documents

Publication Publication Date Title
BR0012568A (en) Phosphate transport inhibitors
WO2002087555A3 (en) Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
PT1143967E (en) USE OF ANTICONVULSIVE DERIVATIVES FOR THE TREATMENT OF SAWS IN SALVAS
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
DE60018978D1 (en) USER AUTHENTICATION IN MEDICAL SYSTEMS
EE04528B1 (en) Aralam laminates for use in therapy for spirofurop ridins
TR200103216T2 (en) Pyrimidinone compositions
TR200100805T2 (en) they Tetrahidropiridoet
HK1033278A1 (en) Pharmaceutical preparation for use in anti-asthma therapy.
HK1050860A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
WO2002028353A3 (en) Phosphate transport inhibitors
BR0110034A (en) Phosphate Transport Inhibitors
MXPA04004372A (en) Heterocyclic derivatives of glycinamide and their medical use.
DE69907926D1 (en) 1,2,4-TRIAZOL-3-THION COMPOUNDS
DE60032884D1 (en) BLOOD TREATMENT SYSTEM
TR200103125T2 (en) Anticonvulsant derivatives for use in improving autism.
EA200000909A1 (en) FORM VI 5,6-DICHLOR-2- (ISOPROPYLAMINO) -1- (b-L-RIBOFURANOSIL) -1H-BENZIMIDAZOLE
AU2001232053A1 (en) System for the extracorporeal treatment of blood
PT1212119E (en) USE OF CIAMEMAZINE IN THE TREATMENT OF BENZODIAZEPINES SUBMITTED WEAR
BR9914722A (en) Anticonvulsant derivatives useful in the treatment of alcohol dependence, addiction and abuse
PT1043025E (en) TREATMENT OF CARCINOMA OF THE RENAL CELL
IT1290910B1 (en) 2-OPTICALLY ACTIVE AMINOTETRALINE, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT, ACTIVE
PT1052991E (en) USING LOPERAMID FOR THE TREATMENT OF MICROBIAL INFECTIONS
BR0008791A (en) Anticonvulsant derivatives, useful in treating essential tremor
ATE392213T1 (en) USE OF GAMMA-GT INHIBITORS FOR THE TREATMENT OF CHRONIC DEGENERATIVE DISEASES

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]